SpringWorks Therapeutics, Inc. (SWTX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 01:47PM EDT. Market open.
| Previous close | 43.35 |
| Open | 44.93 |
| Bid | 43.61 x 400 |
| Ask | 43.87 x 100 |
| Day's range | 42.12 - 45.10 |
| 52-week range | 18.00 - 53.92 |
| Volume | |
| Avg. volume | 1,199,680 |
| Market cap | 3.242B |
| Beta (5Y monthly) | 0.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GuruFocus.com
SpringWorks Therapeutics Inc (SWTX) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
Insights into SWTX's robust Q1 performance, strategic initiatives, and forward-looking financial health.
- GuruFocus.com
SpringWorks Therapeutics Inc (SWTX) Reports Q4 and Full Year 2023 Financial Results
R&D Expenses: R&D expenses increased to $150.5 million in 2023, reflecting investment in clinical trials and drug development. Net Loss: Net loss widened to $325.1 million in 2023, with a loss per share of $5.15.
© 2024 Yahoo. All rights reserved.